Stryker Corporation has announced a definitive agreement to acquire Inari Medical for $3.8 billion, gaining the FlowTriever and ClotTriever thrombectomy systems for treating life-threatening blood clots.
Stryker Corporation has announced a definitive agreement to acquire Inari Medical for approximately $3.8 billion in cash, representing a 35% premium to Inari's 30-day volume-weighted average share price.
Inari Medical is the market leader in mechanical thrombectomy for venous thromboembolism (VTE), with its FlowTriever (pulmonary embolism) and ClotTriever (deep vein thrombosis) systems used in over 60,000 procedures annually.
Why This Matters
- VTE causes approximately 300,000 deaths annually in the US
- Inari 2025 revenue: ~$580 million (+42% YoY)
- FlowTriever reduces PE mortality vs. anticoagulation alone
- Highly complementary with Stryker's Neurovascular business
The acquisition is expected to be immediately accretive to Stryker's adjusted EPS following close, anticipated in mid-2026 pending regulatory review.
Stryker President and CEO Kevin Lobo stated: "Inari's differentiated technologies and strong commercial execution align perfectly with our strategy to lead in high-growth, high-acuity interventional markets."
